Drugs / MIVALSECOVATEIN
MIVALSECOVATEIN
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05925127 | Oct 2023 → May 2024 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 2/3 | NCT05975060 | Sep → Nov 2023 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05973006 | Aug 2023 → Apr 2024 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05767606 | Mar → Jul 2023 | COVID-19, pneumococcal infection | Medical University of Vienna | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIVALSECOVATEIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068266 ↗ |
| Known as | Mivalsecovateina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068266 ↗ |
| Known as | Mivalsecovateine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068266 ↗ |
| Known as | NVX-CoV2601 | “The co-administration of the Omicron-adapted COVID-19 vaccine from Novavax (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine (PCV20) has not been previously investigated.” PMID 39756693 ↗ Jan 20253“The Novavax COVID-19 vaccine, NVX-CoV2601, contains XBB.1.5 recombinant spike protein” PMID 39824198 ↗ Jan 2025 |
| Modality | Vaccine | “the Omicron-adapted COVID-19 vaccine from Novavax (NVX-CoV2601)” PMID 39756693 ↗ Jan 2025 |
| Route | Intramuscular | “one IM injection on Day 0” NCT05925127 ↗ |